[go: up one dir, main page]

WO2000015210A3 - Use of mycophenol acid and its derivatives for the treatment of virus diseases - Google Patents

Use of mycophenol acid and its derivatives for the treatment of virus diseases Download PDF

Info

Publication number
WO2000015210A3
WO2000015210A3 PCT/US1999/021003 US9921003W WO0015210A3 WO 2000015210 A3 WO2000015210 A3 WO 2000015210A3 US 9921003 W US9921003 W US 9921003W WO 0015210 A3 WO0015210 A3 WO 0015210A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
derivatives
methods
treatment
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/021003
Other languages
French (fr)
Other versions
WO2000015210A2 (en
Inventor
Roger Tung
Ann Kwong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority to AU60374/99A priority Critical patent/AU6037499A/en
Priority to EP99969023A priority patent/EP1113794A2/en
Priority to JP2000569794A priority patent/JP2002524502A/en
Publication of WO2000015210A2 publication Critical patent/WO2000015210A2/en
Publication of WO2000015210A3 publication Critical patent/WO2000015210A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

The invention relates to methods of treating viral diseases caused by viruses of the family Flaviviridae, or by a virus which targets the mammalian liver as a main repository for viral replication. The methods of this invention involve the use of mycophenolic acid or its derivatives, particularly mycophenolate mofetil alone, or in combination with other anti-viral agents. The methods of this invention are particularly useful in treating hepatitis B virus, hepatitis C virus, and dengue virus viral infections.
PCT/US1999/021003 1998-09-14 1999-09-14 Use of mycophenol acid and its derivatives for the treatment of virus diseases Ceased WO2000015210A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU60374/99A AU6037499A (en) 1998-09-14 1999-09-14 Methods of treating viral disease
EP99969023A EP1113794A2 (en) 1998-09-14 1999-09-14 Methods of treating viral disease
JP2000569794A JP2002524502A (en) 1998-09-14 1999-09-14 Treatment of viral diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10014498P 1998-09-14 1998-09-14
US60/100,144 1998-09-14
US13842999P 1999-06-10 1999-06-10
US60/138,429 1999-06-10

Publications (2)

Publication Number Publication Date
WO2000015210A2 WO2000015210A2 (en) 2000-03-23
WO2000015210A3 true WO2000015210A3 (en) 2000-05-25

Family

ID=26796841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/021003 Ceased WO2000015210A2 (en) 1998-09-14 1999-09-14 Use of mycophenol acid and its derivatives for the treatment of virus diseases

Country Status (4)

Country Link
EP (1) EP1113794A2 (en)
JP (1) JP2002524502A (en)
AU (1) AU6037499A (en)
WO (1) WO2000015210A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
WO1997016204A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
US5688529A (en) * 1993-10-01 1997-11-18 Syntex (U.S.A) Inc. Mycophenolate mofetil high dose oral suspensions
WO1998048840A1 (en) * 1997-04-29 1998-11-05 Schering Corporation Polyethylene glycol-interferon alpha conjugates for therapy of infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688529A (en) * 1993-10-01 1997-11-18 Syntex (U.S.A) Inc. Mycophenolate mofetil high dose oral suspensions
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
WO1997016204A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
WO1998048840A1 (en) * 1997-04-29 1998-11-05 Schering Corporation Polyethylene glycol-interferon alpha conjugates for therapy of infection

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GONG, Z. J. (1) ET AL: "Differential anti - hepatitis B virus activity in vitro of three potent of inosine monophosphate dehydrogenase inhibitors: Mycophenolic acid ( MPA ), 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide ( EICAR ) and ribavirin.", JOURNAL OF HEPATOLOGY, (1998) VOL. 28, NO. SUPPL. 1, PP. 103. MEETING INFO.: 33RD ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER LISBON, PORTUGAL APRIL 15-18, 1998 EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER., XP000889851 *
GONG, Z. J. ET AL: "Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in cultures of primary and immortalized human hepatocytes.", HEPATOLOGY, (1997) VOL. 26, NO. 4 PART 2, PP. 226A. MEETING INFO.: 48TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES CHICAGO, ILLINOIS, USA NOVEMBER 7-11, 1997, XP000889646 *
PLATZ K P ET AL: "Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation.", TRANSPLANTATION PROCEEDINGS, (1998 AUG) 30 (5) 2232-3., XP000889658 *
PLATZ K P ET AL: "Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation.", TRANSPLANTATION PROCEEDINGS, (1998 JUN) 30 (4) 1468-9., XP000889647 *

Also Published As

Publication number Publication date
AU6037499A (en) 2000-04-03
JP2002524502A (en) 2002-08-06
WO2000015210A2 (en) 2000-03-23
EP1113794A2 (en) 2001-07-11

Similar Documents

Publication Publication Date Title
WO2007076034A3 (en) Anti-viral compounds
WO2007081517A3 (en) Anti-viral compounds
EA200300023A1 (en) 3'-PROCEDURES 2'-DEOXY-β-L-NUCLEOSIDES
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
WO2008133753A3 (en) Anti-viral compounds
WO2009039248A8 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
MXPA04012779A (en) 2' and 3'-nucleoside prodrugs for treating flaviviridae infections.
EA200300810A1 (en) VIRUS CAUSING THE DISEASE OF RESPIRATORY TRACKS IN RECEPTIVE MAMMALS
EA200701850A1 (en) CONNECTIONS OF TRICYCLIC NUCLEOSIDES (OPTIONS), PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND METHOD OF TREATING OR PREVENTING VIRAL INFECTIONS IN MAMMALIANS
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
EA200300819A1 (en) DERIVATIVES OF NUCLEOSIDES AS AN INHIBITORS RNA-DEPENDENT RNA VIRUS POLYMERASE
WO2003055896A3 (en) Anti-viral 7-deaza l-nucleosides
WO2007070556A3 (en) N-(6-membered aromatic ring)-amido anti-viral compounds
EA200201279A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL HEPATITIS C
EA200500723A1 (en) COMPOUNDS OF BENZOFURANE, COMPOSITIONS AND METHODS OF TREATMENT AND PREVENTION OF INFECTIONS, CAUSED BY THE HEPATITIS C VIRUS, AND RELATED DISEASES
DE69434931D1 (en) METHOD FOR THE SELECTIVE INACTIVATION OF VIRAL REPLICATION
EA200700243A1 (en) METHODS OF TREATMENT OF HEPATITIS C
ATE475660T1 (en) ANTIVIRAL COMPOUNDS
ATE289519T1 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS-RELATED DISEASES
BR9913935A (en) Methods of treatment and prevention of infection caused by at least one virus of the family of flaviviridae and disease associated with said infection in a living host
ATA29997A (en) METHOD FOR INACTIVATING LIPID-ENVIRONED VIRUSES
EP1107961A4 (en) INHIBITION AND TREATMENT OF HEPATITIS B-VIRUS AND FLAVIVIRUS BY HELIOXANTHIN AND ANALOGA OF THEM
EP1256348A4 (en) REMEDIES AGAINST HEPATITIS C
EA200700718A1 (en) COMBINED ANTI-VIRAL COMPOSITIONS CONTAINING KASTANOSPERMIN AND METHODS OF THEIR APPLICATION
WO2010107742A3 (en) Methods and compositions of treating a flaviviridae family viral infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 569794

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999969023

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999969023

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999969023

Country of ref document: EP